Pfizer reported better than expected quarterly profits Tuesday behind cost cuts and growth in some non-Covid-related products in ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Healthcare was the only sector in the red by afternoon trading on the ASX, following a similar retreat on Wall Street ...

Pharma giant Merck on Tuesday announced in its earnings report that it would halt all shipments of HPV drug Gardasil to China ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth to ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...